Dashboard
Poor Management Efficiency with a low ROCE of 5.12%
- The company has been able to generate a Return on Capital Employed (avg) of 5.12% signifying low profitability per unit of total capital (equity and debt)
High Debt Company with a Debt to Equity ratio (avg) at times
Healthy long term growth as Net Sales has grown by an annual rate of 6.84% and Operating profit at 13.42%
The company declared very negative results in Mar'25 after flat results in Dec'24
With ROCE of 4.85%, it has a very attractive valuation with a 0.99 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
JPY 7,277,004 Million (Large Cap)
63.00
NA
0.01%
0.61
3.08%
1.06
Total Returns (Price + Dividend) 
Takeda Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Takeda Pharmaceutical Hits Day Low Amid Price Pressure, Closes at JPY 4,234.00
Takeda Pharmaceutical Co., Ltd. saw its stock decline significantly today, contrasting with the Japan Nikkei 225's modest decrease. Over the past month, Takeda's performance has lagged behind the index, with financial metrics indicating challenges such as low returns and a high debt-to-equity ratio amid a drop in net profit.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Foreign Institutions
Held in 0 Schemes (0%)
Held by 2 Foreign Institutions (0.06%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 5.06% vs -7.93% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 220.54% vs -532.55% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 7.45% vs 5.87% in Mar 2024
YoY Growth in year ended Mar 2025 is -25.00% vs -54.52% in Mar 2024






